PHILADELPHIA--(BUSINESS WIRE)--Latus Bio, Inc. (Latus), a biotechnology company pioneering advances in AAV gene therapy, has announced new research published today in Science Translational Medicine, ...

LEXINGTON, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced ...

Let us help you with your inquiries, brochures and pricing requirements Request A Quote Download PDF Copy Download Brochure Accurate viral vector characterization in ...

LEXINGTON, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced the first ...

NEW YORK & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apertura Gene Therapy, a biotechnology company opening opportunities in genetic medicine for treating debilitating diseases with limited options, today ...

In this talk, David Apiyo, Manager of Application Development at Sartorius (Göttingen, Germany), proposes a method that extends the use of AAVX biosensors to determine empty-to-full capsid ratios.

CAMBRIDGE, Mass., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation ...

In the mid-1990s, Hiroyuki Nakai, now an adeno-associated virus (AAV) researcher at the Oregon Health and Science University, moved to the United States. Nakai quickly became fascinated with the ...

Solid Biosciences is bidding for enhanced delivery in gene therapy as it drives uptake of its proprietary capsid and initiates Phase III enrolment for its lead programme. Image credit: metamorworks ...

PackGene to Offer Barcoded High-Throughput AAV Capsid Screening Kits Through Strategic License Agreement with Children's Medical Research Institute Provided by PR Newswire Aug 26, 2025, 4:30:00 AM ...